Compass Therapeutics, Inc. (NASDAQ:CMPX) Director Purchases $115,813.00 in Stock

Compass Therapeutics, Inc. (NASDAQ:CMPXGet Rating) Director Carl Gordon acquired 64,700 shares of the business’s stock in a transaction on Wednesday, May 11th. The stock was bought at an average cost of $1.79 per share, for a total transaction of $115,813.00. Following the completion of the transaction, the director now directly owns 14,690,178 shares of the company’s stock, valued at $26,295,418.62. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.

Shares of Compass Therapeutics stock traded down $0.01 during trading on Wednesday, hitting $2.44. The stock had a trading volume of 342 shares, compared to its average volume of 267,686. The business has a fifty day moving average of $1.58 and a two-hundred day moving average of $2.09. Compass Therapeutics, Inc. has a fifty-two week low of $1.25 and a fifty-two week high of $5.92.

Compass Therapeutics (NASDAQ:CMPXGet Rating) last announced its earnings results on Monday, May 9th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.07. Analysts anticipate that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current fiscal year.

A number of research analysts recently commented on the company. LADENBURG THALM/SH SH began coverage on Compass Therapeutics in a research note on Tuesday, March 15th. They set a “buy” rating and a $7.00 price objective for the company. B. Riley began coverage on Compass Therapeutics in a research note on Tuesday, January 18th. They issued a “buy” rating and a $10.00 price target for the company. HC Wainwright began coverage on Compass Therapeutics in a research note on Friday, January 21st. They issued a “buy” rating and a $11.00 price target for the company. Finally, Zacks Investment Research cut Compass Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, April 4th. One equities research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company. According to MarketBeat, Compass Therapeutics has an average rating of “Buy” and an average price target of $9.14.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Difesa Capital Management LP purchased a new stake in shares of Compass Therapeutics during the fourth quarter valued at $33,000. Millennium Management LLC purchased a new stake in Compass Therapeutics in the 4th quarter worth about $35,000. Mirabella Financial Services LLP purchased a new stake in Compass Therapeutics in the 4th quarter worth about $60,000. Qube Research & Technologies Ltd lifted its stake in Compass Therapeutics by 81.9% in the 1st quarter. Qube Research & Technologies Ltd now owns 52,842 shares of the company’s stock worth $72,000 after acquiring an additional 23,789 shares in the last quarter. Finally, JPMorgan Chase & Co. purchased a new stake in Compass Therapeutics in the 4th quarter worth about $75,000. 66.04% of the stock is owned by institutional investors and hedge funds.

About Compass Therapeutics (Get Rating)

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, develops proprietary antibody-based therapeutics to treat multiple human diseases. The company's product candidates include CTX-009, an investigational bispecific antibody, which is in Phase II clinical trial for biliary tract cancers, as well as Phase Ib clinical trial for colorectal and ovarian cancer; CTX-471, a monoclonal antibody product candidate that is in Phase I clinical trial for patients with solid tumors, such as small cell lung cancer and melanoma; and CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 for oncology area.

Further Reading

Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.